Merck and Ridgeback announce U.S. government to purchase 1.4 million additional courses of molnupiravir
KENILWORTH, N.J. — Merck and Ridgeback Biotherapeutics announced Tuesday that the United States government will exercise two of its options to purchase a total of 1.4 million additional courses of molnupiravir, an investigational oral antiviral medicine, if the medicine is granted Emergency Use Authorization (EUA) or approval by the U.S. Food and Drug Administration (FDA),
